Meeder Asset Management Inc Akebia Therapeutics, Inc. Transaction History

Meeder Asset Management Inc

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 09, 2021	SELL	$2.83 - $4.2 $764 - $1,134	-270 Closed	0 $0
Q1 2021 Apr 28, 2021	BUY	$2.92 - $5.06 $788 - $1,366	270 New	270 $1,000
Q3 2020 Nov 02, 2020	SELL	$2.39 - $13.08 $24,559 - $134,410	-10,276 Closed	0 $0
Q2 2020 Aug 11, 2020	BUY	$6.67 - $13.58 $32,582 - $66,338	4,885 Added 90.61%	10,276 $139,000
Q1 2020 May 15, 2020	BUY	$4.1 - $10.24 $2,664 - $6,656	650 Added 13.71%	5,391 $42,000
Q4 2019 Feb 13, 2020	BUY	$3.16 - $6.73 $10,453 - $22,262	3,308 Added 230.84%	4,741 $30,000
Q3 2019 Oct 17, 2019	SELL	$3.55 - $5.4 $8,097 - $12,317	-2,281 Reduced 61.42%	1,433 $6,000
Q2 2019 Aug 05, 2019	BUY	$4.1 - $8.05 $15,227 - $29,897	3,714 New	3,714 $18,000
Q1 2019 Apr 16, 2019	SELL	$5.41 - $8.73 $17,896 - $28,878	-3,308 Closed	0 $0
Q4 2018 Jan 17, 2019	BUY	$5.39 - $9.15 $13,496 - $22,911	2,504 Added 311.44%	3,308 $19,000
Q3 2018 Nov 02, 2018	SELL	$7.44 - $10.65 $111 - $159	-15 Reduced 1.83%	804 $0
Q2 2018 Jul 24, 2018	BUY	$9.15 - $11.34 $6,761 - $8,380	739 Added 923.75%	819 $0
Q1 2018 May 03, 2018	SELL	$9.53 - $15.68 $1,334 - $2,195	-140 Reduced 63.64%	80 $1,000
Q4 2017 Feb 02, 2018	BUY	$14.24 - $19.59 $3,132 - $4,309	220	220 $3,000

120

54.8M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $324M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Meeder Asset Management Inc with notifications on news.